Company intelligence / Profile preview

Straumur

Houston, Texas, United Statesarstraumur.com ↗

Ownership: Private
Development stage: Commercial

Overview

Stramsen Biotech has a robust pipeline of 33 plant-based drug candidates targeting a wide range of indications. Eleven of these are in early-stage clinical trials. Some products are reportedly already used internationally. The company is focused on confirming safety and efficacy for FDA approval and expanding into Western markets.

Therapeutic areas: NephrologyMen's HealthOncologyEndocrinologyHematologyRheumatologyCardiovascularNeurologyInfectious Diseases
Modalities: Small molecule (plant-derived)Herbal medicine
Industry: Biotech

Partnerships

GEM Global Yield LLC SCS (lead investor/private equity partner)

Beyond the preview

Go deeper on Straumur.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Straumur.

Explore the full profile